Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by National Pension Service

Key Points

• The National Pension Service has reduced its investment in Teva Pharmaceutical Industries by 46.3%, holding approximately $25.44 million worth of shares after selling 1,429,497 shares.
• Analysts have mostly given Teva a buy rating, with a consensus price target of $24.71, reflecting positive sentiment despite recent stock market performance.
• Insiders have sold a total of 65,001 shares valued at nearly $997,000 over the last quarter, indicating a potential shift in internal confidence regarding the company's stock.

National Pension Service lessened its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 46.3% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,655,392 shares of the company's stock after selling 1,429,497 shares during the period. National Pension Service owned about 0.15% of Teva Pharmaceutical Industries worth $25,443,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of TEVA. Golden State Wealth Management LLC purchased a new position in shares of Teva Pharmaceutical Industries during the 1st quarter worth approximately $39,000. New Age Alpha Advisors LLC bought a new position in Teva Pharmaceutical Industries in the 1st quarter valued at approximately $43,000. Marshall & Sterling Wealth Advisors Inc. bought a new position in shares of Teva Pharmaceutical Industries during the 4th quarter valued at $44,000. Compagnie Lombard Odier SCmA bought a new position in shares of Teva Pharmaceutical Industries during the 1st quarter valued at $54,000. Finally, Banque Cantonale Vaudoise bought a new position in shares of Teva Pharmaceutical Industries during the 1st quarter valued at $74,000. Institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE:TEVA traded down $0.5050 on Tuesday, hitting $17.5550. 12,485,740 shares of the company were exchanged, compared to its average volume of 12,168,104. Teva Pharmaceutical Industries Ltd. has a 1-year low of $12.47 and a 1-year high of $22.80. The stock's 50 day moving average price is $16.69 and its 200 day moving average price is $16.24. The company has a current ratio of 1.06, a quick ratio of 0.77 and a debt-to-equity ratio of 2.45. The firm has a market capitalization of $20.13 billion, a P/E ratio of -109.72, a price-to-earnings-growth ratio of 1.06 and a beta of 0.62.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.64 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The company had revenue of $4.18 billion for the quarter, compared to analyst estimates of $4.34 billion. During the same period in the prior year, the company earned $0.61 earnings per share. The firm's revenue was up .3% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. Sell-side analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. UBS Group decreased their target price on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a report on Thursday, June 26th. Bank of America raised their price objective on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a report on Monday, April 28th. Finally, The Goldman Sachs Group initiated coverage on shares of Teva Pharmaceutical Industries in a research note on Friday, June 6th. They issued a "buy" rating and a $24.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the stock. According to MarketBeat.com, Teva Pharmaceutical Industries currently has an average rating of "Buy" and an average target price of $24.71.

Insider Buying and Selling

In related news, EVP Matthew Shields sold 6,206 shares of the company's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total transaction of $105,626.12. Following the completion of the sale, the executive vice president owned 9,989 shares of the company's stock, valued at approximately $170,012.78. This represents a 38.32% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Eric A. Hughes sold 52,742 shares of the stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $799,568.72. The disclosure for this sale can be found here. Insiders sold a total of 65,001 shares of company stock worth $996,958 in the last 90 days. Insiders own 0.49% of the company's stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.